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cGMPInhibition of constitutive nitric oxide (cNO) production inhibits SGLT1 activity by a reduction in the afﬁnity for
glucose without a change in Vmax in intestinal epithelial cells (IEC-18). Thus, we studied the intracellular path-
way responsible for the posttranslational modiﬁcation/s of SGLT1. NO is known to mediate its effects via cGMP
which is diminished tenfold in L-NAME treated cells. Inhibition of cGMP production at the level of guanylyl cy-
clase or inhibition of protein kinase G also showed reduced SGLT1 activity demonstrating the involvement of
PKG pathway in the regulation of SGLT1 activity. Metabolic labeling and immunoprecipitation with anti-SGLT1
speciﬁc antibodies did not show any signiﬁcant changes in phosphorylation of SGLT1 protein. Tunicamycin to in-
hibit glycosylation reduced SGLT1 activity comparable to that seen with L-NAME treatment. The mechanism of
inhibition was secondary to decreased afﬁnity without a change in Vmax. Immunoblots of luminal membranes
from tunicamycin treated or L-NAME treated IEC-18 cells showed a decrease in the apparent molecular size of
SGLT1 protein to 62 and 67 kD, respectively suggesting an alteration inprotein glycosylation. The deglycosylation
assay with PNGase-F treatment reduced the apparent molecular size of the speciﬁc immunoreactive band of
SGLT1 from control and L-NAME treated IEC-18 cells to approximately 62 kD from their original molecular size
of 75 kD and 67 kD, respectively. Thus, the posttranslational mechanism responsible for the altered afﬁnity of
SGLT1 when cNO is diminished is secondary to altered glycosylation of SGLT1 protein. The intracellular pathway
responsible for this alteration is cGMP and its dependent kinase.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Nitric oxide (NO), the ubiquitous signaling molecule is known to play
a critical role in the major physiological processes of the gastrointestinal
(GI) tract such as intestinal motility, intestinal injury carcinogenesis and
apoptosis [1–4]. It has been shown to have contradicting roles as one con-
tributing to intestinal inﬂammation during pathophysiological conditions
as in Inﬂammatory Bowel Disease (IBD) when it is produced in large
amounts (inducibleNO/iNO) or as being aprotective agent inmaintaining
intestinal integrity during normal physiological conditionswhen it is pro-
duced in small quantities (constitutive NO/cNO) [5–7]. NO is also known
to regulate absorption and secretion in the intestine [8–13] where again
the regulation depends on the condition under study, either physiological
or pathophysiological. NO being amajor cell signalingmolecule can exert
its activity primarily by activating soluble guanylate cyclase and thus acti-
vating cyclic GMP dependent kinases which initiates a cascade of physio-
logical changes [14–16]. Over the years, research has shown evidences ofm).
ights reserved.involvement of NO, cGMP and protein kinase G as signiﬁcant signal trans-
duction pathway intermediates, orchestrating the regulation of a wide
range of inter and intracellular mechanisms by phosphorylation of a
wide variety of target proteins [17–21].
The mammalian SGLT1 is the major Na-dependent glucose co-
transporter on the brush border of intestinal epithelial cells. It is argu-
ably the most functionally studied co-transporter and has been shown
to play a central role not only in active sugar transport but has also
been shown to be a participant in various cellularmechanisms of the in-
testine including its role in the cytoprotection of intestinal epithelial
cells [22–24]. There are innumerable studies showing the regulation of
SGLT1 by different signal transduction pathways notably Protein Kinase
C (PKC) and Protein Kinase A (PKA) at the level of both transcription
and translation in the intestinal epithelial cells [25–30].
Previous in vivo and in vitro studies have shown that the primary
Na-dependent glucose co-transporter SGLT1, in the BBM of the
enterocytes is directly regulated by cNO [11,13]. It was also shown
that the inhibition of cNO production by L-NAME, inhibits the activity
of SGLT1 in rat intestinal epithelial cells (IEC-18) and the mechanism
of inhibition was secondary to a decrease in the afﬁnity of the co-
transporter for its substrate with no change in Vmax [13]. This study
also showed that there was no difference in the steady state expression
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the control. Therefore it is unlikely that cNO inhibition has an effect on
SGLT1 mRNA transcription. Hence, the decreased afﬁnity of SGLT1 ap-
pears to be due to modiﬁcation of the SGLT1 protein and therefore it
becomes important to understand the molecular mechanisms and the
related intracellular signaling pathway that may be involved in the reg-
ulation of SGLT1 activity in normal physiological conditions.
It is well known that NO could bring changes in phosphorylation
through the activation of cGMP activated Protein Kinase G (PKG)
[31,32]. Therefore, the ﬁrst hypothesis of the present study was that
the PKG pathway is involved in the regulation of SGLT1 protein activity.
We hypothesized further that the effect of inhibition of PKG pathway
may result in changes in (a) direct phosphorylation of SGLT1 protein, al-
tering the intrinsic activity of the transporter, (b) phosphorylation of
other target proteins that may regulate the co-transporter, inﬂuencing
its activity.
Therefore, the aim of the present studywas to analyze themolecular
effect of inhibition of intracellular cNO production on Na-glucose co-
transporter SGLT1 in rat intestinal epithelial cells and also aims to
study the predictable involvement of NO mediated protein kinase G
pathway in the above said SGLT1 protein regulation through regulatory
mechanisms such as alteration of protein phosphorylation or glycosyla-
tion. This study further discusses the importance of the requirement of
cNO for the efﬁcient activity of Na-glucose co-transporter SGLT1 in nor-
mal physiological conditions.2. Materials and methods
2.1. Tissue culture
Rat IEC-18 cells (CRL-1589 American Type Culture Collection, Ma-
nassas, VA/Rockville, MD, USA) between passages 5 and 25 and grown
to 10 days post conﬂuence were used for all the experiments. Cells
were grown in high glucose Dulbecco's modiﬁed Eagle's medium
(Invitrogen, Grand Island, NY) supplemented with 0.2 U/ml of insulin,
0.5 mM β-hydroxybutyrate (Sigma Chemical, St. Louis, MO) and 10%
fetal calf serum (HyClone, Fischer Scientiﬁc, Pittsburgh, PA) and incu-
bated at 37 °Cwith 10% CO2. Cells grown on permeablemembrane sup-
ports were used for all the uptake experiments and for the preparation
of brush border membrane (BBM) protein extracts.2.2. Treatment and cell viability assessment
Cells were treated with 1 mM of Nw-Nitro-L-arginine methyl ester
hydrochloride (L-NAME) (Cayman chemicals, Ann Arbor, MI) to inhibit
cNO production or vehicle alone 24 h prior to the experiment. The cells
were treated with 50 μM of Protein kinase G inhibitor, Guanosine 3′,5′-
cyclic Monophosphorothioate, β-Phenyl-1,N2-etheno-8-bromo-, Rp-
Isomer, Sodium Salt (RP-cGMP) (Calbiochem, La Jolla, CA) and 500 μM
of guanylyl cyclase inhibitor 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-
one (ODQ) (Calbiochem, La Jolla,CA) for 24 h independently of each
other to inhibit Protein Kinase G pathway. Cells were also treated with
1 μg/ml of tunicamycin (Santa Cruz Biotech. Inc. CA) for 48 h to inhibit
glycosylation. To ensure viability of cells after tunicamycin treatment,
Lactate dehydrogenase (LDH) levels were measured using Cytotoxicity
Detection Kit (Roche Diagnostics) according to the manufacturer's
protocol.2.3. Detection of cGMP levels
The level of cGMP in control and L-NAME treated IEC-18 cells was
quantitatively measured using cyclic GMP (direct) EIA immunoassay
Kit (Enzo Life Sciences, Inc. Ann Arbor, MI) according to the
manufacturer's protocol.2.4. Metabolic labeling
IEC-18 cell monolayers (10 days post conﬂuent)werewashed once in
phosphate-free DMEM and incubated for 1 h at 37 °C. Cells were then in-
cubated at 37 °Cwith the samemedium containing 1 mCi/ml carrier-free
[32P] orthophosphate for 1 h to equilibrate the intracellular ATP pools
with labeled phosphate. The adherent cells were washed three times
with Krebs-Ringer HEPES solution (120 mM NaCl, 5.6 mM KCl, 1.2 mM
MgCl2, 1.2 mM CaCl2, 20 mMHEPES-Tris, pH 7.4) and lysed by the addi-
tion of 400 μl/well ice-cold modiﬁed radioimmunoprecipitation buffer
(10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1%
sodium deoxycholate, pH 7.4) containing protease (1 μM pepstatin A,
250 μM phenylmethylsulfonyl ﬂuoride, 1 μg/ml leupeptin, 1 μg/ml
aprotinin) and phosphatase inhibitors (10 mM sodium ﬂuoride, 50 mM
sodiumpyrophosphate, and 1 μMokadaic acid) for 1 h at 4 °Cwith agita-
tion. RIPA extracts were centrifuged at 20,000 ×g for 30 min at 4 °C and
the supernatant was used for immunoprecipitation.
2.5. Immunoprecipitation
IEC-18 protein extracts were precleared by the addition of 100 μl
(3 mg) of Protein A-agarose beads for 1 h at 4 °C. The protein was
immunoprecipitated overnight at 4 °C by the addition of the speciﬁc
SGLT1 antibody (Abcam Inc. Cambridge, MA), 10 μl of antisera on end-
over-end continuous mixing followed by 1-h incubation with Protein
A-agarose beads (3 mg in 100 μl in RIPA buffer) at 22 °C. The
immunoadsorbents were washed three times with ice-cold RIPA buffer
prior to the addition to 50 μl of protein sample buffer (62.5 mM Tris–
HCl, pH 6.8, 20% glycerol, 2% SDS, 5% β-mercaptoethanol, and 0.01%
bromophenol blue) and incubated for 30 min at 22 °C, and then re-
solved by native gel electrophoresis (10%), with radiolabeled proteins
detected by autoradiography. The relative amounts of 32P incorporated
into the protein were estimated.
2.6. Na-glucose co-transport in IEC-18 cells
Glucose uptake experiments were done in IEC-18 cells grown to
10 days post-conﬂuenceon6well transwell plateswithpermeablemem-
brane (Polyester membrane thickness 10 μm, pore size 0.4 μm) support.
To beginwith, cells werewashed and incubatedwith Leibowitz-15medi-
um supplemented with 10% fetal bovine serum and gassed with 100% O2
at room temperature for an hour. The cells were then washed and incu-
bated for 10 min with Na-free medium containing 130 mM trimethyl
ammonium chloride (TMA-Cl), 4.7 mM KCl, 1.2 mM KH2PO4, 1 mM
MgSO4, 1.25 mM CaCl2, 20 mM HEPES. Uptakes were performed at de-
sired time intervals in reaction medium containing either 130 mM NaCl
or 130 mM TMA-Cl in HEPES medium with 10 μCi of 3H-O-methyl glu-
cose (OMG) and100 μMof cold substrateOMG. The reactionwas stopped
with ice cold Na-free medium. The cells were then incubated with 1 N
NaOH for 20 min at 70 °C. To the digested cells from each reaction placed
in separate scintillation vials, 4 ml of scintillation ﬂuid (Ecoscint A,
National Diagnostics) was added. Radioactivity was determined in a scin-
tillation counter (LS 6500; Beckman Coulter, Fullerton, CA).
2.7. Real-time quantitative PCR (RTQ-PCR)
Total RNA was isolated from control and treated IEC-18 cells using
RNeasy Plus Mini kit (Qiagen). First strand cDNA was synthesized by
using oligo (dT) primer, random hexamers, and SuperScript III Reverse
Transcriptase (Invitrogen). The cDNAs synthesized were used as tem-
plates for RTQ-PCR by using TaqMan universal PCRmastermix (Applied
Biosystems) according to themanufacturer's protocol. β-Actin RTQ-PCR
was run along with SGLT1 to normalize their expression between con-
trol and treated samples. RTQ-PCR was performed for 45 cycles at
95 °C for 15 s and 60 °C for 1 min using an ABI 7300 RTQ-PCR system.
Experiments using different dilutions of the SGLT1, and β-actin cDNAs
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were performed in triplicate with RNA isolated from at least three sets
of IEC-18 cells.
2.8. Preparation of BBM
To prepare the BBM, IEC-18 cells were grown in 150 mm petri dish
(Corning, NY) to 10 days post-conﬂuence. BBM was prepared by CaCl2
precipitation and differential centrifugation as preciously described
[33]. BBM were suspended in appropriate protein preparation buffer
for each experiment.
2.9. Western blot
Western blot analyses of BBM from IEC-18 cells were performed as
described earlier [34]. BBM solubilized in RIPA buffer (50 mMTris · HCl
pH 7.4, 1% Igepal, 150 mMNaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Sodi-
um Orthovandate, 1 mM NaF) containing protease inhibitor and phos-
phatase inhibitor cocktails (inhibitor cocktails purchased from SAFC
Biosciences) wasmixedwith sample buffer (100 mMTris, 25% glycerol,
2% SDS, 0.01% bromophenol blue, 10%-β-mercaptoethanol, pH 6.8) and
separated on an 8% polyacrylamide gel. The separated proteins were
transferred to PVDFmembrane (Immobilon-pSQ,Millipore) and probed
with SGLT1 antibody raised in rabbit (Abcam Inc. Cambridge, MA). Goat
anti-rabbit coupled to horseradish peroxidase (Jackson Immunoresearch
Laboratories, West Grove, PA) was used as a secondary antibody.
The resulting chemiluminescence was measured by autoradiography.
SGLT1 abundance was quantitated using a densitometric scanner (Alpha
Innotech-FlourChem™ SP).
2.10. Deglycosylation assay
This was done based on the protocol by Alphonso et al., 2006. In this
assay, N-linked deglycosylation of SGLT1 was done by treatment with
peptide-N4-(N-acetyl-glucosaminyl) asparagines amidase-F (PNGase-
F) (New England BioLabs Inc.) in situ in BBMs of control, tunicamycin
treated and L-NAME treated IEC-18 cells. Brieﬂy, 50 μg of BBM protein
preparation was solubilized in SDS in 50 mM NaCl, 5 mM EDTA, 10%
(vol/vol)β-mercaptoethanol, 20 mMTris–HCl, pH 7.5. The potential in-
hibitory effect of SDS on the activity of the enzyme was neutralized by
sequestering free SDS in an excess of Nonidet P-40. Finally, 2500 units
of PNGase-F were added to the protein in a buffer containing 50%
glycerol, 50 mMNaCl, 5 mMEDTA and 20 mMTris–HCl, pH 7.5 and in-
cubated for 1 h at 37 °C. Deglycosylated samples were separated by
SDS-PAGE and analyzed by Western blot analysis as described above.
2.11. Protein determination
Total protein for all the samples in this study was measured by the
Bradford method, using the Bio-Rad protein assay kit (Hercules, CA)
with BSA as standard.
2.12. Statistical analysis
Results are represented as means ± SE of experiments performed
and calculated with GraphPad InStat program. All uptake experiments
were done in triplicate. The unpaired Student's t-test was performed
for statistical analysis. A p value of less than 0.05 was considered
signiﬁcant.
3. Results
3.1. Effect of inhibition of PKG pathway on SGLT1 activity in IEC-18 cells
The two intermediate components of PKG pathway, Guanylyl
cyclase and cGMP dependent Protein Kinase G were inhibited for 24 hin separate experiments and SGLT1 activitywas estimated using glucose
uptake experiments. Inhibition of PKGwith 50 μMof RP-cGMP (Fig. 1A)
and inhibition of guanyl cyclase with 500 μMof ODQ (Fig. 1B) showed a
signiﬁcant inhibition in SGLT1 activity comparable to that seen with L-
NAME treatment, showing the involvement of the pathway in the regu-
lation of SGLT1 activity. To further conﬁrm this, the level of the second
messenger of PKG pathway, cGMP, was measured in control and L-
NAME treated cells. There was a 10 fold reduction in the level of cGMP
in L-NAME treated cells compared to control (Fig. 2) thus conﬁrming
the role of PKG pathway and its initiator, NO in the regulation of
SGLT1 activity.3.2. Effect of L-NAME in SGLT1 protein phosphorylation in IEC-18 cells
To investigate if changes in NO/cGMP pathway would bring changes
in the phosphorylation levels of SGLT1 protein, control and L-NAME treat-
ed IEC-18 cells were metabolically labeled with 32P and immunopreci-
pitated with anti-SGLT1 speciﬁc antibodies. The immunoprecipitated
protein was then resolved by PAGE and analyzed by autoradiography
(Fig. 3A). SGLT1 protein from L-NAME treated IEC-18 cells did not show
any signiﬁcant changes in phosphorylation compared to SGLT1 protein
from control IEC-18 cells (Fig. 3B). Thus, the regulation of SGLT1 protein
seen with the inhibition of cNO in IEC-18 cells was not due to protein
phosphorylation changes.3.3. Effect of tunicamycin on SGLT1 activity in IEC-18 cells
To study if glycosylation changes would regulate the inhibition of
SGLT1 protein activity by L-NAME treatment, alternatively IEC-18 cells
were treated with tunicamycin, a known inhibitor of glycosylation.
LDH assay was performed to evaluate the cytotoxicity of tunicamycin
on IEC-18 cells. The percentage viability of IEC-18 cells was not altered
when treated with tunicamycin at a concentration of 1 μg/ml for 48 h
and this was used as the ideal treatment concentration and condition.
Na-dependent glucose uptake was performed in tunicamycin treated
cells and was found to be signiﬁcantly reduced compared to control
IEC-18 cells (Fig. 4A). Thus, tunicamycin treatment inhibited Na-
dependent glucose uptake.3.4. Effect of tunicamycin on SGLT1 kinetics in IEC-18 cells
As mentioned earlier, the previous study showed that the inhibition
of SGLT1 activity by reduced cNO levels (L-NAME treatment) is second-
ary to altered afﬁnity of the co-transporter for glucosewith no change in
the maximal rate of glucose uptake [13]. To relate if the inhibition of
SGLT1 activity by tunicamycin was by a mechanism similar to that
seen with L-NAME treatment, kinetic uptake studies were performed
as a function of increasing extracellular glucose concentration at a 30 s
time period. As the concentration of extracellular glucose increased,
the uptake of Na-dependent glucose was stimulated and subse-
quently became saturated in all conditions. From these experimental
data, kinetic parameters were derived using GraphPad Prism 4
(San Diego, CA). Kinetic studies showed that the maximal rate
(Vmax) of glucose uptake was not altered by tunicamycin treatment
(4.2 ± 0.2 nmol/mg·pro·sec in control and 5.5 ± 0.5 in tunicamycin),
but the afﬁnity (Km) of the transporter for glucose was seen reduced
signiﬁcantly in tunicamycin treated IEC-18 cells compared to control
(5.4 ± 1.0 mM in control and 22.5 ± 0.7 in tunicamycin treated;
n = 3, p b 0.05). This shows that the mechanism of inhibition of
Na-dependent uptake by tunicamycin is secondary to a decrease in
the afﬁnity of SGLT1 protein for the substrate with no change in
the co-transporter numbers and is similar to the mechanism seen
with SGLT1 activity inhibition by L-NAME treatment.
Fig. 1.A. Effect of inhibition of protein kinaseGon SGLT1 activity. Na-dependentOMGuptakewas signiﬁcantly reduced in IEC-18 cells treatedwith 50 μMof ProteinKinaseG inhibitor RP-cGMP.
B. Effect of inhibition of guanylyl cyclase on SGLT1 activity. IEC-18 cells treated with 500 μM of guanylyl cyclase inhibitor ODQ showed a signiﬁcant inhibition in the activity of SGLT1.
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Previous study by Coon et al., 2008 had shown that L-NAME had no
effect on SGLT1 mRNA in IEC-18 cells. In this present study, real-time
PCR analysis was done to see if tunicamycin had any effect on SGLT1
mRNA expression. It was observed that tunicamycin had no effect on
SGLT1 mRNA expression (Fig. 4B) and the relative mRNA abundance
of SGLT1 remained unchanged in both tunicamycin and control IEC-18
cells. This result further establishes that the effect of tunicamycin on
SGLT1 protein is comparable to that seen when cNO production was
inhibited by L-NAME treatment.
3.6. Immunoblotting analysis
SGLT1 protein was recognized as a band of approximately 72 kD in
the BBM preparation of IEC-18 cells. However, in the tunicamycin and
L-NAME treated cell BBM protein extract there was a decrease in the
molecular mass of the SGLT1 protein to 62 and 67 kD respectively
(Fig. 5A). Furthermore, densitometric analysis showed that there was
no signiﬁcant difference in the abundance of the SGLT1 speciﬁc band
in both tunicamycin and L-NAME treated IEC-18 cells compared to con-
trol (Fig. 5B). Immunoblots were normalized with an anti-ezrin anti-
body to assure equivalence of loading. This apparent reduction in the
molecular weight in tunicamycin and L-NAME treated cells suggests
alterations in glycosylation of the SGLT1 protein in the luminal
membrane.
3.7. Deglycosylation assay
To know whether the observed changes in the molecular mass of
SGLT1 were due to loss of glycosylation of the protein in tunicamycin
and L-NAME treated IEC-18 cells, the BBM protein preparation was in-
cubated with N-glycosidase F (PNGase-F) enzyme to enable deglycosyl-
ation. The PNGase-F treatment reduced the apparent molecular size of
the speciﬁc immunoreactive band of SGLT1 from control IEC-18 cells
to approximately 62 kD. The SGLT1 speciﬁc bands from tunicamycin
and L-NAME treated IEC-18 cells also lined up against the control after
deglycosylation assay (Fig. 6). This conﬁrms that the reduction in the
apparent molecular weight of the SGLT1 protein speciﬁc band in theFig. 2. cGMP levels in control and L-NAME treated IEC-18 cells. Measurement of cGMP
levels showed a 10 fold decrease of cGMP in L-NAME treated cells compared to control.control, tunicamycin treated and L-NAME treated IEC-18 cells after
PNGase-F treatment is due to complete deglycosylation of the SGLT1
protein.4. Discussion
The purpose of the present study was to understand the underlying
molecular mechanism of the alteration of SGLT1 protein activity, seen
during the inhibition of cNO production in IEC-18 cells. Coon et al.,
2005 showed previously in rabbit enterocytes, that the inhibition of
cNO production inhibited SGLT1 activity, secondary to a decrease in
the afﬁnity of the co-transporter. Similar results were also seen in IEC-
18 cells, were again L-NAME treatment inhibited SGLT1 activity second-
ary to a decrease in the afﬁnity of the co-transporter for glucose with no
change in the co-transporter numbers and unchanged expression of
SGLT1 mRNA [13]. Based on these observations, the present study was
aimed to decipher the intracellular pathway and the posttranslational
mechanisms involved in the altered afﬁnity of SGLT1 for its substrate
when cNO production was inhibited by L-NAME treatment (Fig. 7).
It is well known in the literature that NO activates soluble guanylate
cyclase and thus participates in the transduction pathway involving cy-
clic GMP dependent kinases (Protein Kinase G/PKG) which initiates a
cascade of changes in protein phosphorylation of serine/threonine resi-
dues in potential biological targets [31,32,35–39]. Therefore, the initial
objective of this study was to conﬁrm the involvement of PKG pathway
in SGLT1 regulation. The measurement of the secondary messenger of
the PKG pathway, cGMP, showed a signiﬁcant decrease in its level in
the L-NAME treated cells compared to control. Also, inhibition of PKG
pathway at the level of Guanylyl cyclase and at the level of PKG showedFig. 3. A) A representative autoradiograph of immunoprecipitated 32P-labeled
SGLT1 from control and L-NAME treated IEC-18 cells. B) Densitometric analysis of
immunoprecipitated 32P-labeled SGLT1 from control and L-NAME treated cells
(n = 3). Densitometric quantiﬁcation of immunoprecipitated 32P-labeled SGLT1
showed no signiﬁcant alteration in the levels of protein phosphorylation in
L-NAME treated cells compared to control.
Fig. 4. A. Effect of Tunicamycin on SGLT1 activity. Tunicamycin treatment signiﬁcantly inhibited SGLT1 activity. This inhibition is comparable to the inhibition of SGLT1 activity that was
previously seenwith L-NAME treatment. B. Relative abundance of SGLT1mRNA in control and tunicamycin treated cells (n = 3). Real time PCRanalysis demonstrated that themessage for
SGLT1 was unaffected in IEC-18 cells treated with Tunicamycin.
Fig. 5. A–B: Western blot analysis of BBM protein SGLT1 from control, tunicamycin and
L-NAME treated IEC-18 cells. Representative blots of three separate experiments and the
graphs represent densitometric quantiﬁcation of single represented blots. The SGLT1 protein
was recognized as a 72 kD band. But the molecular mass of SGLT1 from tunicamycin and
L-NAME treated cells was decreased to 62 and 67 kD respectively. Densitometric analysis
showed no signiﬁcant alteration of protein abundance in all the three conditions. Immuno-
blots were normalized with an anti-ezrin antibody to assure equivalence of loading.
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inhibition of cNO production by L-NAME. Thus, inhibition of PKG path-
way at different levels showed similar changes in SGLT1 activity,
conﬁrming that NO regulates SGLT1 through PKG pathway. This inhibi-
tion of NO/cGMP pathway at the key regulatory steps, as well as the re-
duction in the production of the second messenger, cGMP, would
ultimately result in the non-activation of cGMP dependent kinase en-
zymewhich would further result in the non-phosphorylation of its bio-
logical targets having a direct or an indirect effect on the SGLT1 protein
and its activity.
As mentioned before, there are innumerable studies showing the
regulation of SGLT1 by different signal transduction pathways notably
Protein Kinase C (PKC) and Protein Kinase A (PKA) at the level of both
transcription and translation in the intestinal epithelial cells. SGLT1 con-
tains a number of potential consensus sites of PKA and PKC [26,40]. The
consequences of SGLT1 protein phosphorylation include alteration of its
catalytic rate, shifting its apparent afﬁnity for substrate and inhibitors
and its redistribution between surface and internal membrane compo-
nents [26]. Protein Kinase A is also known to affect the sorting and con-
formation of SGLT1 protein expression in the membrane of the
epithelial cells, causing an increase in the co-transporter afﬁnity [41].
It is also well known that NO could bring changes in phosphorylation
through the activation of cGMP activated Protein Kinase G (PKG)
[31,32]. Hence, looking for changes in the phosphorylation in SGLT1
protein itself seemed to be the obvious ﬁrst step in the analysis of post
translational modiﬁcation after the inhibition of cNO production.
Rat SGLT1 (SLC5A1) has 11 serine and 8 threonine amino acid resi-
dues as potential targets of changes in phosphorylation. Though there
were no previous reports available in the regulation of SGLT1 through
phosphorylation changes through PKG, we presumed that changes inFig. 6. Effect of deglycosylation on SGLT1 byWestern blot analysis. Detection of SGLT1 in
BBM protein control, L-NAME treated and tunicamycin treated of IEC-18 cells. Deglycosyl-
ation assay with PNGase-F reduced the apparent molecular size of SGLT1 protein in con-
trol and L-NAME treated cells to approximately 62 kD in line with the SGLT1 protein
from tunicamycin treated cells due to complete deglycosylation. The ﬁgure is the repre-
sentative blot of three separate experiments.
Fig. 7. The ﬂow chart summarizes the pathway responsible for the alteration of glycosyl-
ation of SGLT1 protein by the inhibition of cNO production. Inhibition of cNO production
results in non-activation of cGMP mediated PKG pathway, resulting in the non-activation
of NAG transferase enzyme which otherwise is responsible for the glycosylation of SGLT1
protein in the normal physiological conditions.
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tional modiﬁcation that could be seen with SGLT1 in the present study.
Metabolic Labeling with 32P and immunoprecipitation with two different
anti-SGLT1 antibodies showed no change in the level of phosphorylation
between control and L-NAME treated IEC-18 cells. In a separate experi-
ment, SGLT1 protein was immunoprecipitated from BBM preparation
and probed with anti-phosphoserine and anti-phosphothreonine anti-
bodies and here again no change in the phosphorylation levels of
the SGLT1 protein was found (data not shown) between control and
L-NAME treated IEC-18 cells. These results conﬁrmed that phosphoryla-
tion is not the posttranslationalmechanism responsible for the altered ac-
tivity of SGLT1 after the inhibition of cNO production in IEC-18 cells. This
result was quite intriguing in a way that it turned out to be not the out-
come that was expected.
This leads into the possibility of cGMP/PKG pathway acting indirect-
ly on SGLT1 protein through a target protein that may inﬂuence SGLT1
activity. The NO/cGMP pathway could induce acute phosphorylation
of N-acetylglucosamine (NAG) transferase I enzyme which is involved
in the terminal glycosylation of target proteins [17,42]. This led us to as-
certain that glycosylation would be a possible mechanism of posttrans-
lational alteration seen with SGLT1 after L-NAME treatment. For this,
IEC-18 cells were treated with tunicamycin and SGLT1 activity was esti-
mated followed by molecular analysis of the SGLT1 protein, in the next
series of experiments.
First, IEC-18 cells were treated with tunicamycin a known inhibitor
of terminal glycosylation. It was found that tunicamycin inhibited Na-
dependent glucose co-transport by about 55% comparable to the inhibi-
tion of SGLT1 activity seenwith L-NAME treatment. To extend this ﬁnd-
ing further, kinetic parameters of SGLT1 inhibition by tunicamycinwere
done and analyzed. It was found that the mechanism of inhibition of
SGLT1 activity by tunicamycin was secondary to a decrease in the afﬁn-
ity (Km) rather than any change in its maximum activity (Vmax). The
kinetic parameters conﬁrmed that the mechanism of inhibition of
SGLT1 activity by both L-NAME and tunicamycin was by a similarmechanism. To further check if there was any change in the expression
of the SGLT1 reactive protein after the two treatment conditions, West-
ern blot analyses were done. It was observed in the Western blot anal-
yses that SGLT1 protein which is generally seen as an approximately
72 kD protein, had a reduced molecular mass of approximately 67 kD
and 62 kD in L-NAME and tunicamycin treated samples respectively.
The changes in the molecular mass of the protein are unarguably due
to the loss of glycosylation of the protein. The higher molecular weight
of SGLT1 protein in L-NAME treated cells compared to that of SGLT1
protein in tunicamycin treated cells is presumably due to incomplete
or partial cleavage of the oligosaccharide residues attached to it. Since
tunicamycin blocks complete N-glycosylation of the proteins, the highly
reduced molecular weight of 62 kD of SGLT1 protein is due to its com-
plete deglycosylation. This was further conﬁrmed by the deglycosyla-
tion assay where complete deglycosylation by PNGase-F treatment
reduced the apparent molecular weight of the SGLT1 protein speciﬁc
band in the control and L-NAME treated IEC-18 cells to 62 kD, similar
to the size of the SGLT1 protein obtained by tunicamycin treatment.
Whereas, the molecular weight of SGLT1 protein from tunicamycin
treated cells remained unchanged by PNGase-F treatment. Regardless
of this observation, therewas no signiﬁcant change in the relative abun-
dance of SGLT1 reactive protein in the BBM of both L-NAME and
tunicamycin treated IEC-18 cells compared to control.
Though there aremany studies that mention phosphorylation as the
common post-translational mechanism involved in the regulation of
SGLT1, there are very few reports of glycosylation being responsible
for the altered activity of SGLT1. A study by Mate et al., 2006 showed
that the regulation of sodium-glucose cotransporter SGLT1 in the intes-
tine of hypertensive rats was due to alterations in protein glycosylation
resulting in changes in Vmax. But this study differs from the observa-
tions seen in the current study by the fact that the change in glycosyla-
tion resulted in a different kinetic mechanism of alteration in protein
activity; Km in the current study and Vmax in the reference study.
This is a very signiﬁcant observation of the present study and requires
further investigation. We hypothesize that changes in glycosylation at
theN-terminalmay cause subtle changes in the conﬁrmation of the pro-
tein resulting in the modiﬁcation of the substrate binding site and in
turn the afﬁnity of the protein without altering the protein trafﬁcking
to the brush border membrane. The present study may be the ﬁrst to
show glycosylation as a post-translational mechanism responsible for
alteration of protein afﬁnity.
To further conﬁrm that the regulation of SGLT1 protein was only
through the post-translational mechanism, relative mRNA abundance
of SGLT1 was measured by RTQ-PCR. It was found that the treatment
of IEC-18 cells with L-NAME or tunicamycin did not have any effect on
the mRNA abundance of SGLT1, thus conﬁrming that the altered mech-
anism of SGLT1 activity is through the modiﬁcation of its protein itself
rather than any change at the level of transcription.
This study emphasizes the importance of requirement of cNO in
small quantities for the efﬁcient activity of Na-glucose co-transporter
SGLT1 in normal physiological conditions. Pharmacological inhibition
of NO production may have detrimental effects in normal physiological
processes. NO, is an ubiquitous and versatile signalingmolecule respon-
sible for the regulation of diverse physiological processes. Though the
inappropriate overproduction of iNO plays a very important role
in pathogenesis and aggravation of inﬂammation in Inﬂammatory
Bowel Diseases (IBD), small amounts of cNO are known to play an effec-
tive role in maintaining the integrity of intestinal mucosa. It was
shown in feline small intestine that basal NO synthesis and release
is a protective mechanism in the intestine during inﬂammatory con-
ditions and its inactivation exacerbates tissue injury [43]. In normal
rat intestine, NO synthase (NOS) especially neuronal NO synthase
(nNOS) which is the predominant one in the intestine was found
to regulate the expression of iNOS via modulation of nuclear factor
kappa B which is an activator of iNO synthase (iNOS) thus keeping
a check on its expression [44].
1214 S. Arthur et al. / Biochimica et Biophysica Acta 1838 (2014) 1208–1214In addition, inhibition of SGLT1 activity by L-NAME treatment has
shown to trigger a compensatory mechanism through the activation
of BBMNa/H exchanger (NHE3) so as to maintain Na gradient in the in-
testinal epithelial cells [13]. It is also interesting to note that when the
physiological levels of NOwere increased by a NO donor, SGLT1 activity
was signiﬁcantly stimulated secondary to the increase in the afﬁnity of
the co-transporter for glucose (unpublished data).
The summary of the intercellular pathway responsible for the alter-
ation SGLT1 by inhibition of cNO is given in Fig. 7. In conclusion,we have
found that the decrease in the activity of sodium-dependent D-glucose
transporter during the inhibition of constitutive nitric oxide production
is due to the changes in the post-translational modiﬁcation of the pro-
tein, speciﬁcally glycosylation.
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